For generations, the question of whether a treatment truly slows human aging has demanded the most unforgiving of timekeepers: a human lifetime. A new meta-analysis of 51 longevity studies, published in Nature Medicine, brings science closer to a more practical answer, identifying which epigenetic clocks — biological measures of aging inscribed in our DNA — respond most reliably when people take drugs or change how they live. The work does not yet prove that these clocks measure aging itself, but it narrows the search, pointing researchers toward the instruments most worthy of deeper trust.
Study identifies most reliable epigenetic clocks for testing longevity interventions
Responsiveness alone does not establish a biomarker as valid
Mark
Why does it matter which biomarker responds to an intervention? Can't researchers just wait and see who lives longer?
Mimi
In theory, yes. In practice, that takes decades and costs enormous amounts of money. If you can measure something that changes quickly and reliably predicts the outcome you care about, you can run shorter, cheaper trials and get answers faster.
Mark
So these epigenetic clocks are like a speedometer for aging?
Mimi
More like a dashboard with multiple gauges. Some gauges respond to the same interventions consistently. Others barely move. The study found that the most useful ones are those trained to predict mortality or aging pace, not just chronological age.
Mark
What surprised you most about the results?
Mimi
That pharmacological interventions—especially drugs like metformin and TNF-targeting agents—produced such large, measurable changes in these biomarkers. And that the same drug worked differently depending on whether the person was healthy or had disease.
Mark
Does this mean metformin actually slows aging?
Mimi
Not yet. It means metformin changes these biomarkers in ways that correlate with aging. Whether that translates to longer life or better health still needs to be proven in long-term studies.
Mark
What's the next step?
Mimi
Researchers need to link these biomarker changes to real clinical outcomes—actual disease prevention, healthspan, lifespan. Until then, these clocks are promising tools, not proof.
O Pulso
- Aging research has been trapped in a paradox: proving a treatment extends life requires waiting for people to die, making trials impractically long and expensive.
- A curated analysis of 51 human longevity studies found that second-generation epigenetic clocks — especially those trained to predict mortality pace — shifted most consistently in response to interventions, while older first-generation clocks largely failed to respond.
- Metformin and TNF-targeting anti-inflammatory drugs produced the largest biomarker changes, hinting that aging interventions may work through shared metabolic and immune pathways involving AMPK, mTOR, and TNF.
- People with existing disease showed stronger biomarker responses than healthy populations, a finding that could reshape how future trials are designed and who gets enrolled.
- Researchers caution that a clock that moves in response to treatment is not yet proof that aging itself has slowed — the harder work of linking these biomarkers to actual changes in lifespan or healthspan still lies ahead.
For generations, the question of whether a treatment truly slows human aging has demanded the most unforgiving of timekeepers: a human lifetime. A new meta-analysis of 51 longevity studies, published in Nature Medicine, brings science closer to a more practical answer, identifying which epigenetic clocks — biological measures of aging inscribed in our DNA — respond most reliably when people take drugs or change how they live. The work does not yet prove that these clocks measure aging itself, but it narrows the search, pointing researchers toward the instruments most worthy of deeper trust.
Scientists have long faced a stubborn practical problem: determining whether a drug or lifestyle change genuinely slows human aging requires waiting decades to see who lives longer. A new analysis of 51 longevity studies, published in Nature Medicine, proposes a faster path, identifying which biological clocks — aging signals written into DNA through chemical modifications called methylation — respond most reliably to interventions designed to extend life or healthspan.
The researchers drew on the TranslAGE database, aggregating data from major genomic repositories and clinical trials, then calculated 16 different epigenetic clocks across all studies. The central finding was unambiguous: not all aging clocks behave equally. Those trained specifically to predict mortality or the pace of aging showed the strongest and most consistent responses. Of the 51 studies, 19 showed significant decreases in methylation-based aging measures after treatment, five showed increases, and most showed no detectable change.
The largest effects came from pharmacological treatments and lifestyle interventions. Metformin, a widely used diabetes drug, produced especially large shifts in explainable biomarker subscores tied to inflammation, brain function, and metabolism. TNF-targeting agents — drugs that suppress immune inflammation — modified nearly all second-generation biomarkers in patients with arthritis or inflammatory bowel disease, suggesting these treatments may act through shared pathways involving AMPK, mTOR, or TNF. Mediterranean diet interventions also drove meaningful changes, with the epigenetic proxy for triglycerides shifting in six of seven dietary studies.
Among individual clocks, DunedinPACE showed the greatest overall responsiveness, while PCGrimAge offered the strongest statistical evidence of change. GrimAgeV2, SystemsAge, and PCPhenoAge also performed well across multiple interventions. Explainable clocks, which decompose aging into multiple biological subscores rather than a single number, proved especially useful for understanding how interventions actually work.
The researchers also found that population health status shaped results: the same intervention tended to produce larger biomarker changes in people with disease than in healthy individuals — a pattern with direct implications for trial design. Yet they were careful to distinguish responsiveness from validity. A clock that reliably shifts in response to treatment does not automatically confirm that aging has slowed or that life will be extended. Establishing these measures as true surrogate endpoints — short-term signals that predict long-term outcomes — requires linking them to clinically meaningful results. That harder validation work remains ahead, even as the findings clarify which clocks are most worth pursuing.
Scientists have long faced a practical problem: testing whether a drug or lifestyle change actually slows human aging requires waiting decades to see who lives longer. A new analysis of 51 longevity studies suggests a faster path forward, identifying which biological clocks—measures of aging written in our DNA—respond most reliably to interventions meant to extend life or healthspan.
The work, published in Nature Medicine, examined how different epigenetic aging biomarkers behaved across a range of human trials. Researchers curated data from the TranslAGE database, which pulled together studies from the European Molecular Biology Laboratory, the Gene Expression Omnibus, and clinical trials, then calculated 16 different epigenetic clocks across all of them. The core finding was clear: not all aging clocks are created equal. Those specifically trained to predict mortality or the pace of aging itself showed the strongest and most consistent responses to interventions. Among the 51 studies analyzed, 19 showed significant decreases in DNA methylation aging measures after treatment, while five showed increases. Most others produced no detectable change.
The strongest effects came from two categories of intervention. Pharmacological treatments—drugs, in other words—produced larger average changes in biomarkers than any other approach. Lifestyle interventions, particularly versions of the Mediterranean diet, also drove substantial shifts. Metformin, a common diabetes medication, emerged as particularly potent, with explainable biomarkers showing especially large changes in inflammatory, brain, and metabolic system scores. TNF-targeting agents, drugs designed to dampen immune inflammation, modified nearly all second-generation biomarkers in people with arthritis or inflammatory bowel disease. The pattern suggested that these drugs may work partly through inflammatory and metabolic pathways involving AMPK, mTOR, or TNF itself.
Certain biomarkers proved more reliable than others. DunedinPACE showed the greatest overall responsiveness to intervention-related changes, while PCGrimAge provided the strongest statistical evidence. Other second-generation clocks—GrimAgeV2, SystemsAge, and PCPhenoAge—also demonstrated significant decreases across multiple interventions. First-generation clocks, by contrast, were less responsive. The researchers also found that explainable clocks, which break aging down into multiple subscores rather than a single number, offered greater biological insight into how interventions actually worked. The epigenetic proxy for triglycerides, for instance, shifted significantly in six of seven dietary intervention studies, suggesting it could become a useful tool for assessing dietary effects.
Population health status mattered too. The same intervention often produced larger biomarker changes in people with disease than in healthy populations, a finding with practical implications for trial design. Study duration and sample characteristics also influenced how responsive biomarkers were to treatment. These patterns could help researchers choose which interventions and biomarkers to pair in future trials, potentially shortening studies and reducing the number of participants needed.
But the researchers offered an important caveat. Responsiveness is not the same as validity. A biomarker that changes reliably in response to treatment does not automatically prove that the treatment actually slows aging or extends life. To serve as a true surrogate endpoint—a short-term measurement that predicts longer-term outcomes—these biomarkers would need to be linked to clinically meaningful results: actual changes in disease, healthspan, or lifespan. That validation work remains ahead. The findings suggest which clocks deserve further investigation, but they do not yet establish any of them as proven measures of aging itself.
Citações Notáveis
Responsiveness alone does not establish a DNAm biomarker as a valid surrogate endpoint or show that an intervention slows aging— Study authors, Nature Medicine
Biomarker changes still need to be linked with clinically meaningful outcomes and long-term effects on disease, healthspan, or lifespan— Study authors, Nature Medicine
Quer a matéria completa?
Leia o original em News-Medical ↗
Technology